US2007004629A1PendingUtilityA1

K9 and equine joint health food supplement and method of administering

40
Individually held — no corporate assignee on recordPriority: Jan 24, 2001Filed: Sep 7, 2006Published: Jan 4, 2007
Est. expiryJan 24, 2021(expired)· nominal 20-yr term from priority
Inventors:Terri StilesAhmad Alkayali
A61P 19/02A61K 35/32A23L 33/17A23J 1/10
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Kolla2 powder compositions, methods of preparing the compositions, and use of the compositions in treating degenerative joint diseases, joint defects, hip displasia, and osteoarthritis. The compositions are orally administered to K9's and equines in need of cartilage cell repair in a daily dietary food supplement.

Claims

exact text as granted — not AI-modified
1 . A method of preparing Kolla2 powder for oral administration as a dietary supplement to a K9 or equine animal which comprises, separating at lease one member of the group consisting of cartilage derived from warm-blooded animals containing partially water-soluble, denatured Collagen Type II protein and subdividing such cartilage into dose amounts for therapeutically effective levels.  
     
     
         2 . The method of  claim 1  wherein said Kolla2 powder has an average molecular weight of about 50,000 daltons.  
     
     
         3 . The kolla2 of  claim 2 , wherein said kolla2 is extracted from desiccated avian sternal cartilage and avian cartilage collagen type II protein.  
     
     
         4 . A method of positively influencing cartilage production and growth in a K9 or equine animal with a joint disorder, comprising orally administering to said animal an effective daily cartilage-inducing amount of kolla2.  
     
     
         5 . The method of  claim 4 , wherein said connective tissue disorder is selected from the group consisting of degenerative joint diseases, joint defects, hip displasia, and osteoarthritis.  
     
     
         6 . The method of  claim 4 , wherein for a K9 less than 50 pounds said effective daily dosage amount is between about 100 mg and 10,000 mg.  
     
     
         7 . The method of  claim 4 , wherein for a K9 less than 50 pounds said effective daily dosage amount is between about 500 mg and 4,000 mg.  
     
     
         8 . The method of  claim 4 , wherein for a K9 less than 50 pounds said effective daily dosage amount is between about 700 mg and 1,000 mg.  
     
     
         9 . The method of  claim 4 , wherein for a K9 weighing more than 50 pounds said effective daily dosage amount is between about 500 mg and 10,000 mg.  
     
     
         10 . The method of  claim 4 , wherein for a K9 weighing more than 50 pounds said effective daily dosage amount is between about 700 mg and 4,000 mg.  
     
     
         11 . The method of  claim 4 , wherein for a K9 weighing more than 50 pounds said effective daily dosage amount is between about 1,400 mg and 3,000 mg.  
     
     
         12 . The method of  claim 4 , wherein for a horse, for each 100 pounds of body weight, said effective daily dosage amount is between about 100 mg and 10,000 mg.  
     
     
         13 . The method of  claim 4 , wherein for a horse, for each 100 pounds of body weight, said effective daily dosage amount is between about 500 mg and 3,000 mg.  
     
     
         14 . The method of  claim 4 , wherein for a horse, for each 100 pounds of body weight, said effective daily dosage amount is between about 1000 mg and 2,500 mg.  
     
     
         15 . A method of daily nutritional supplement of kolla2 as a preventative for degenerative joint disease in a K9 or equine animal, comprising orally administering to an individual a daily dosage of kolla2 having an average molecular weight of between about 45,000 and 65,000 daltons.  
     
     
         16 . A method for treating an animal, such as a dog or horse having a degenerative joint disorder comprising administering to said animal a composition comprising collagen type II and having an average molecular weight of between about 45,000 and 65,000 daltons.  
     
     
         17 . The method of  claim 16  wherein the composition is in powder form.  
     
     
         18 . The method of  claim 16  wherein said connective tissue disorder is selected from the group consisting of degenerative joint diseases, joint defects, hip displasia, osteoarthritis, polychondritis, and menier's disease.  
     
     
         19 . The method of  claim 16 , wherein for a K9 less than 50 pounds said effective daily dosage amount is between about 100 mg and 10,000 mg.  
     
     
         20 . The method of  claim 16 , wherein for a K9 less than 50 pounds said effective daily dosage amount is between about 500 mg and 4,000 mg.  
     
     
         21 . The method of  claim 16 , wherein for a K9 less than 50 pounds said effective daily dosage amount is between about 700 mg and 1,000 mg.  
     
     
         22 . The method of  claim 16 , wherein for a K9 weighing more than 50 pounds said effective daily dosage amount is between about 500 mg and 10,000 mg.  
     
     
         23 . The method of  claim 16 , wherein for a K9 weighing more than 50 pounds said effective daily dosage amount is between about 700 mg and 4,000 mg.  
     
     
         24 . The method of  claim 16 , wherein for a K9 weighing more than 50 pounds said effective daily dosage amount is between about 1,400 mg and 3,000 mg.  
     
     
         25 . The method of  claim 16 , wherein for a horse, for each 100 pounds of body weight, said effective daily dosage amount is between about 100 mg and 10,000 mg.  
     
     
         26 . The method of  claim 16 , wherein for a horse, for each 100 pounds of body weight, said effective daily dosage amount is between about 500 mg and 3,000 mg.  
     
     
         27 . The method of  claim 16 , wherein for a horse, for each 100 pounds of body weight, said effective daily dosage amount is between about 1000 mg and 2,500 mg.

Join the waitlist — get patent alerts

Track US2007004629A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.